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Abstract
Conventional wisdom holds that the best way to treat infection with antibiotics is to ‘hit early and hit hard’. A favoured
strategy is to deploy two antibiotics that produce a stronger effect in combination than if either drug were used alone. But
are such synergistic combinations necessarily optimal? We combine mathematical modelling, evolution experiments, whole
genome sequencing and genetic manipulation of a resistance mechanism to demonstrate that deploying synergistic
antibiotics can, in practice, be the worst strategy if bacterial clearance is not achieved after the first treatment phase. As
treatment proceeds, it is only to be expected that the strength of antibiotic synergy will diminish as the frequency of drug-
resistant bacteria increases. Indeed, antibiotic efficacy decays exponentially in our five-day evolution experiments. However,
as the theory of competitive release predicts, drug-resistant bacteria replicate fastest when their drug-susceptible
competitors are eliminated by overly-aggressive treatment. Here, synergy exerts such strong selection for resistance that an
antagonism consistently emerges by day 1 and the initially most aggressive treatment produces the greatest bacterial load,
a fortiori greater than if just one drug were given. Whole genome sequencing reveals that such rapid evolution is the result
of the amplification of a genomic region containing four drug-resistance mechanisms, including the acrAB efflux operon.
When this operon is deleted in genetically manipulated mutants and the evolution experiment repeated, antagonism fails
to emerge in five days and antibiotic synergy is maintained for longer. We therefore conclude that unless super-inhibitory
doses are achieved and maintained until the pathogen is successfully cleared, synergistic antibiotics can have the opposite
effect to that intended by helping to increase pathogen load where, and when, the drugs are found at sub-inhibitory
concentrations.
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Introduction
Our arsenal of antimicrobials boasts a wide diversity of drugs
and we continue to invest in the search for new ones [1]. Yet
bacteria adapt so readily to their ambient environment that all
antibiotics in clinical use have bacteria that resist them [2,3]. A
Staphylococcus aureus infection traced in vivo yielded over thirty de novo
mutations from a 12-week therapy, each mutation conferring an
increase in drug resistance [4]. With such a rapidly evolving foe
and antibiotic discovery programmes waning substantially [3],
determining optimisation principles that maintain the efficacy of
the antibiotic repertoire already in our possession represents one of
the keenest challenges confronting the scientific community.
And yet drug-resistance evolution has been called ‘conceptually
uninteresting’ [5]. This view is the result of assuming a fixed
timeline: a pathogen is treated with antibiotics, resistance traits
emerge, sweep through the population and fix. The more efficient
the drug, the greater selection for resistance and the sooner
resistance fixes. The only mitigating action we can take is hit early,
hit hard and kill drug-susceptible cells before they accumulate, so
the old argument goes [6].
Bacteria are hardest hit by multi-drug combinations. Developed
for over 70 years [1,7,8], combinations are key in our fight against
microbes [9], viruses [10] and cancers [11]. Combinations said to
be synergistic, where two drugs hit the pathogen much harder
than each drug alone, are highly prized [1,12,13]. Indeed, the
rapid deployment of synergistic antibiotics should, according to the
same logic, be the fastest way of clearing a bacterium.
To make our discussion more precise we say that a pair of
bacteriostatic antibiotics of equal efficacy is synergistic if a 50-50
weighted combination of both drugs inhibits growth more than the
two single-drug treatments when measured over one day of
bacterial growth [8,14–16]. (Strictly speaking, we ask this for all
(h,(12h))-combinations where h is any value between 0 and 100%,
not just 50-50, as shown in Figure 1.) With this definition we can
formulate a null hypothesis, H0: a synergistic drug combination also
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inhibits growth synergistically if the treatment lasts longer than a day. Put
differently, if the 50-50 combination treatment is more efficient
than both single-drug monotherapies on the first day of treatment,
it should also be more efficient on subsequent days to be deemed
synergistic.
Any in vitro test of H0 necessitates the use of antibiotic
concentrations that support measurable population densities, the
treatments we can use to test it are, as a result, necessarily
constrained to a sub-inhibitory dosing regime. We must therefore
question how relevant this study can be to antibiotic use in vivo, we
argue that it is relevant for the following reasons. Drug interactions
are often determined by one-day checkerboards and isoboles [17],
like those illustrated in Figure 1, but by their very nature
checkerboards only provide insight into the interaction inside the
sub-inhibitory regime as isoboles can only be calculated if cells
grow. Moreover, drug concentrations can sweep downwards from
their highest values to sub-inhibitory concentrations during
treatment ([18], Figure 1), repeatedly so for intermittent dosing
regimens [19,20]. The different diffusivities small antibiotic
molecules exhibit in different tissue can create substantial
inhomogeneities in concentration [21] resulting in a potential
spatiotemporal mosaic of selection for resistance [18,22] whereby
treatment can reduce pathogen load in some, but not all, organs
[23]. Indeed, spatial diffusion itself creates concentration gradients
with rapid, super-exponential decay away from a point source. It is
therefore essential to understand how antibiotic combinations
mediate resistance at all dosages within this mosaic, including sub-
inhibitory, particularly as resistance is known to be selected for at
very low concentrations, well below the minimal inhibitory
concentration [24].
Now, we argue that treatments with the greatest short-term
efficacy do not necessarily lead to the lowest bacterial densities
later. A simple construction accounting for both density-depen-
dent and frequency-dependent selection on drug resistance suffices
to explain why. Consider three scenarios with two drugs, ‘A’ and
‘B’. A bacterium is either unchallenged by antibiotics, challenged
with drug A only (or drug B only) or else treated with the optimally
synergistic combination of both, as in Figure 2(a). The no-drug
treatment sees the cells grow, to carrying capacity say, without
selecting for drug-resistant phenotypes. The synergistic combina-
tion inhibits drug-susceptible cells optimally, better than the two
monotherapies, and so, by the end of day 1, the lowest bacterial
load of all is observed in this treatment. However, suppose some
cells exhibit genetic or epigenetic adaptation conferring resistance;
such cells may even have been present in low frequencies at the
start of treatment. It is now in the synergistic line that drug-
resistant phenotypes fare best as they have fewer competitors for
the extracellular metabolites needed for growth.
To clarify how this might arise, imagine a population of bacteria
with two subpopulations of drug-susceptible and resistant cells and
suppose extracellular metabolites are shared equally among all the
growing cells. As the growth of susceptibles is suppressed more at
greater synergies, more metabolites become available for resistant
cells in those treatments. However, resistant cells necessarily grow
faster than susceptible cells do when the drugs are present, with a
greater fitness difference at greater synergies. Thus the total
population density can be increased by the synergy even when the
number of drug-susceptible cells present is reduced. Now, if
resistant cells are absent or at low frequencies at the beginning of
treatment, the exposure to antibiotics must be long enough to
Figure 1. The drug interaction profile, i(h), as defined in
Materials and Methods. The drug interaction profile is closely
related to the two ‘checkerboard’ diagrams shown in (a) and (c). In a
checkerboard, the concentration of both drugs is given on the x and y
axes, bacterial growth inhibition (or population density or some other
fitness measure) is then plotted on the z axis. The contour of all
concentrations that reduce this measure by half is an isobole here
denoted IC50 and figures (a) and (c) show two checkerboard plots
viewed from above. Basal concentrations of both drugs that achieve the
same inhibitory effect in this illustration are D50 and E50, h then
parameterises the equidosage line between these two values. The
fitness measure evaluated along this line is shown in (b) and (d) and we
define the degree of interaction based on this curve, this is i(h). We say
the interaction is synergistic when the drug proportion that minimises
i(h) satisfies 0,h,1 as in (b), we denote the resulting value by hsyn. In
(d) we observe hsyn = 0 or hsyn = 1, in this case the drugs are said to be
antagonistic as i(h) is maximised by some drug combination and
minimised by the monotherapies.
doi:10.1371/journal.pbio.1001540.g001
Author Summary
We take an evolutionary approach to a problem from the
medical sciences in seeking to understand how our
knowledge of rapid bacterial evolution should shape the
way we treat pathogens with antibiotic drugs. We pay
particular attention to combinations of different drugs that
are purposefully used to produce potent therapies.
Textbook orthodoxy in medicine and pharmacology states
one should hit the pathogen hard with the drug and then
prolong the treatment to be certain of clearing it from the
host; how effective this approach is remains the subject of
discussion. If the textbooks are correct, a combination of
two antibiotics that prevents bacterial growth more than if
just one drug were used should provide a better treatment
strategy. Testing alternatives like these, however, is
difficult to do in vivo or in the clinic, so we examined
these ideas in laboratory conditions where treatments can
be carefully controlled and the optimal combination
therapy easily determined by measuring bacterial densities
at every moment for each treatment trialled. Studying
drug concentrations where antibiotic synergy can be
guaranteed, we found that treatment duration was crucial.
The most potent combination therapy on day 1 turned out
to be the worst of all the therapies we tested by the
middle of day 2, and by day 5 it barely inhibited bacterial
growth; by contrast, the drugs did continue to impair
growth if administered individually.
The Smile-Frown Transition
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allow the resistants to achieve densities comparable to the
susceptibles and so the treatment duration then needs to be long
enough for the claim in the previous sentence to be true. This
process is illustrated in Figure 2.
This idea, known as ‘competitive release’ [25] has been tested in
treatments of malaria in vivo using mice [5] where higher drug
concentrations have been shown to select for higher parasite load
but competitive release makes new predictions for antibiotic
therapy, for combinations in particular. First, the optimal
combination is not robust: the best way of deploying a drug pair
depends on how long the treatment lasts. Second, and as a result,
the favoured property of antibiotic synergy is not necessarily
robust to adaptations that confer drug resistance. Not only will
synergy decay with time, it can be lost completely and replaced
with an antagonism because more potent combinations have
paradoxically selected for larger bacterial load. Thus the theory of
competitive release is not consistent with our null hypothesis and
provides an evolutionary rationale for rejecting it.
A toy mathematical model captures the verbal argument
completely and shows that synergy loss can be viewed as a form
of tipping point. Imagine a bacterial population consisting of cells
susceptible to both antibiotics at density S(t), where t is time.
Suppose there is a completely resistant phenotype, R(t), and m is
the mean rate in a random Poisson process by which susceptible
cells gain resistance. The dimensionless variable h between zero
and one controls the drug combination and k(h) = 1+h(12h)
measures the efficiency of each combination at drug concentra-
tions (A,B) = (A0h, B0(12h)). Here A0 and B0 are normalising
concentrations, chosen so that each drug achieves equal inhibitory
effect at a defined time. Note that k(h)is maximised when h=1/2.
This value represents a 50-50 combination therapy whereby
(A,B) = (A0/2, B0/2).
The toy model is the following logistic growth equation
modified to include antibiotics:
d
dt
S~S(1{(SzR)){(k(h)zm)S, ð1aÞ
d
dt
R~R(1{(SzR))zmS, ð1bÞ
where 0vS(0)%1 and R(0) = 0. We therefore begin with
susceptible cells but no resistant ones. Figure 2(b) shows the
population densities that result from this model,
Dt(h) = S(h,t)+R(h,t), plotted as a function of h for increasing values
of time t.
For short times (Equation 1a–b) exhibits synergy because
density is suppressed most by the combination where h=1/2, so
the plot of Dt(h) has the convex, U-shaped ‘smile’ shown in blue in
Figure 2(b). At later times, but only provided m.0, the shape of the
density profile changes and now density is greatest for the 50-50
combination and lowest for the ‘monotherapies’, where h=0 and
h=1. So the plot of Dt(h) now exhibits a near-concave, W-shaped
‘frown’ consistent with antagonism having its maximal value at
h=1/2, as shown in red in Figure 2(b). Density is now maximised
where before it was minimised. We call the resulting passage from
synergy to antagonism the ‘smile-frown transition’, referring to it
on occasion as ‘synergy inversion’ because the convex, synergistic
profile is inverted to form a near-concave, antagonistic one; this is
a different notion of synergy inversion to the one in [26].
If we set m=0, thus preventing the modelled population from
adapting to the drug, it then follows that Dt(h) has a synergistic
profile at all times. In this case the 50-50 combination, represented
Figure 2. Smile-frown transition: a verbal argument and a toy mathematical model. (a) Synergistic drugs suppress drug-susceptible sub-
populations (yellow cells) more than single-drug therapies however, this eliminates competitors of the drug-resistant red cells who grow more rapidly
than the yellow cells would have done at weaker synergies. Thus greater synergy can increase population densities. (b) Solving Equation 1a–b and
plotting population density against drug proportion shows that a short-term synergistic combination (blue) can maximise densities later (red). The red
dots show the path of the optimal combination, note this idealised model is symmetric about h=1/2 but empirical data will not be. (c and d) The
densities of drug-susceptible cells (S on the vertical axis in (c)) and resistants (R on the vertical axis in (d)) are shown at different times where, again, the
blue line denotes a treatment of short duration and the red line denotes a longer treatment. The arrow in (c) represents the loss of S that occurs because
of the drug whereas the arrow in (d) represents the analogous gain in R. For longer treatments the latter more than compensates for the former and by
summing the red and blue lines in (b) and (c), respectively, we obtain the red and blue curves showing population density, D= S+R, in (a).
doi:10.1371/journal.pbio.1001540.g002
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by the value h=1/2, is the optimal combination for all times as it
minimises population density, irrespective of treatment duration.
We tested the veracity of these theoretical predictions using an
evolutionary functional genomics approach that combined evolu-
tion experiments using Escherichia coli, a genomic analysis, the
genetic manipulation of an identified candidate resistance
mechanism and quantitative mathematical modelling. This
approach highlights the molecular mechanism that causes the
synergy loss predicted by theory, whereas the theory alludes to the
generality of the empirical results that we now describe.
Results
Evolution of a Family of Combination Treatments:
Experimental Design
The above predictions are best tested in vitro where the drug
interactions are well-understood and can be rigorously controlled.
We therefore cultured E. coli K12 (MC4100) over a five-day period
using a serial dilution protocol and sixteen different combination
treatments of erythromycin (ERY, a macrolide) and doxycycline
(DOX, a tetracycline), two bacteriostatic translational inhibitors
with an established synergy [14]. The bacteria are first cultured for
24 h in liquid growth medium containing antibiotics at concen-
trations described below and, at the end of the 24 h period, a
random sample of the bacteria is transferred using a standard plate
replicator to inoculate fresh growth medium. This process is
repeated to create a treatment lasting several days.
We began by choosing a pair of normalising, or ‘basal’,
antibiotic concentrations, D50 and E50, in such a way that each
DOX-only and ERY-only monotherapy achieved a 50% reduc-
tion in density when measured at 24 h relative to a zero-drug
control (the basal concentrations D50 and E50 are the IC50 values
of each drug). Each of the sixteen different treatments may
therefore be described by a single pair of concentrations
(D,E)~(hD50,(1{h)E50), ð2Þ
where h is the relative drug proportion. When combined in a 50-
50 ratio at these doses, where h=1/2, a 90% reduction in
bacterial growth at 24 h is achieved, greater than the 50%
reduction achieved by each monotherapy (the data in Figure 3(a)
(Day 1) supports this). We implemented 14 different combination
treatments and two monotherapies at those basal doses with h
ranging in discrete values from 0 and 1/15 to 14/15 and then 1
(19 replicates per treatment; see Section 3.2 in Text S1).
The fixed drug proportion, h, that minimises bacterial density
from the sixteen implemented and determined empirically by
culturing the bacteria for 24 h will be denoted by hsyn in the
following. This value between zero and one denotes the maximally
synergistic combination treatment obtained after fixing the basal
drug concentrations, as shown in Figure 1(b). The time-dependent
optimal combination will be denoted hopt (T) (see Materials and
Methods) and this value represents the combination of ERY and
DOX that minimises density for a treatment of duration T hours.
It follows by design that hopt (T) = hsyn if T is small, less than 24 h,
say.
After calibrating concentrations D and E so that each drug has
equal effect, so hsyn<1/2 in practise as Figure 4(c) shows, the
short-term optimal treatment is a 50-50 combination of both ERY
and DOX. As a reflection of this, the day 1 data in Figure 3(a) then
shows the 50% growth reduction obtained for each monotherapy,
the 90% reduction for the maximally synergistic 50-50 combina-
tion in addition to the growth reduction for all the other
combinations we tested. We can now test our null hypothesis by
asking whether the drug combination that is optimal on day 1, 50-
50 by design, is also optimal on subsequent days. Equation 1
makes a clear prediction: the best therapy on day 1 will be the worst
later.
Smile-Frown Transition: An Empirical Test
The first day’s data exhibits synergism with the lowest short-
term bacterial densities found for near 50-50 combinations of ERY
and DOX, so hsyn<1/2, this can be seen in Figure 5 (shown in
blue). However, the subsequent population dynamics beyond day
1 lead to us to reject H0 for Figure 5 (in red) shows they are
consistent with the theory of competitive release and exhibit the
smile-frown transition before 36 h have elapsed, as we now
explain.
Consistent with the predictions of Equation 1, Figure 4(a)
illustrates how the degree of interaction, I(T), defined in Materials
and Methods, shifts from synergy (where I(T),0; t-test, df=19,
t<26.13, p,0.0001,) to antagonism (where I(T).0; t-test, df=19,
t<6.83, p,0.0001) between 12 h and 36 h. The degree of
interaction thereafter remains positive, denoting antagonism, until
the end of the experiment. This is shown with more detail in
Figure 3. Dynamics of the optimal treatment: the greater the early inhibition, the faster efficacy decays and so the greater the
resulting bacterial density. (a) Using an area under the curve (AUC) inhibition measure expressed as a percentage of growth without antibiotics,
by design a combination of ERY and DOX is optimal on day 1 (red line, ‘50-50’) but an ERY monotherapy is optimal by day two (after the crossing
points of the lines; c.f. Figure 4). The path of three extreme therapies are shown as lines, coloured dots represent the remaining thirteen treatments
colour-coded from green (ERY) to blue (DOX). (b) Exponentially decaying datafits are superimposed upon three treatments from (a).
doi:10.1371/journal.pbio.1001540.g003
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Figure 4(b) where the dynamics of the interaction profile are
shown on an hour-by-hour basis; this illustrates that the interaction
changes at about 30 h.
Examining the apparent change in drug interaction more closely
in Figure 5, at 12 h the interaction profile is synergistic (a-test,
a= 0.6160.05.0, df=13, t#11.22, p,1027, hopt(12h) =
0.4960.01#hsyn; see Materials and Methods and Section 4.3 in
Text S1 for a description of the a-test) but combination treatments
for which h<2/3 (estimated robustly using the a-test described in
Materials and Methods as 0.6560.04) yield the highest observed
population densities by 36 h. As a result, the optimal combination
has changed within two days from a 50-50 combination to an ERY
monotherapy because the interaction profile is now antagonistic (a-test,
a=20.4460.14,0, df=13, t#23.05, p,0.0093, hopt(36h)#0?hsyn;
Section 4.3 in Text S1).
These data were produced for optical density measures of
bacterial growth, but analogous results are obtained using different
notions of fitness. Using an area under the curve measure of
growth inhibition that accounts for both population sizes and
growth rates (Section 4.2 in Text S1) Figure 3(a) shows drug
efficacy approaches zero most rapidly for near 50-50 combination
treatments. The same figure shows the optimal treatment has
shifted in this measure too, to the ERY monotherapy within two
days. For completeness, the smile-frown transition is also seen if we
use colony-forming units to measure bacterial population densities
(Section 7.4 in Text S1).
As a further test for loss of synergy, dose-response checker-
boards and isobolograms were produced using bacteria sampled
from the highly synergistic h<8/15 treatment at the beginning of
days one and five, both are shown in Figure 6. The earlier
checkerboard is consistent with synergism whereas the latter
checkerboard shows a progressing wave of increased resistance,
with synergy at higher drug concentrations and a mixed
interaction apparent at lower concentrations. Figure 6(a, right)
shows isoboles at 60% inhibition that are suggestive of a
suppressive interaction by day 4 in which doxycycline reduces
the inhibitory effect of erythromycin. The white isobole of 50%
inhibition in Figure 6(b) shows a shift from day 1 to 5 that indicates
increased resistance of the population to both ERY and DOX (for
controls that the antibiotics do not degrade significantly when
stored at 4uC for several days see Section 3.2 in Text S1).
Stabilising Synergy: A Genomic Prediction from a
Mathematical Model
Having established the rapid loss of optimality of the most
synergistic combination treatment, at which point the latter
becomes the worst treatment of all, it is essential we understand
the genetic basis of this change. So we first performed a test to
determine whether increased drug resistance was the result of
epigenetic adaptation (Section 3.2 in Text S1).
Samples each of the initially most synergistic drug treatment
and the control treatment without drug were taken from the end of
day 5 and cultured without antibiotics for a further 24 h. The
resulting populations were then all subjected to the most
synergistic drug combination for another 24 h. Consistent with a
likely genetic basis to drug-resistance adaptation, samples from the
short-term synergistic treatment still displayed greater AUC
inhibition when measured relative to the no-drug control
(Wilcoxon signed rank test, W=92, N=10, p,0.001).
Figure 4. Drug interaction profiles are dynamic. (a) The degree of interaction, I(T) defined in Materials and Methods, is shown at different times
from 12 h to 108 h: I(T) is negative for T#24 h denoting synergy, but is positive for all T$36 h denoting antagonism (vertical bars are s.e., 19
replicates). (b) A finer interaction measure than that used in (a), the degree of interaction obtained using the a-test defined in Materials and Methods
produces a locus of drug interaction measures as a function of time. Consistent with (a), this measure changes sign, indicating a change of interaction
near 30 h (note: 2a is plotted). (c) The smile-frown transition resembles a phase transition when applying the a-test to i(h,T) derived from MC4100
density data: the grey line shows the optimal drug combination that minimises i(h,T), the red line shows the maximising combination. As the drug
interaction profile ‘inverts’, the short-term optimal therapy shifts over a very short period to become the worst therapy beyond approximately 30 h.
(The y-axis varies from h=0 (denoting an ERY-monotherapy) to h= 1 (for a DOX-monotherapy), s.e. is shown as a pair of dashed lines.)
doi:10.1371/journal.pbio.1001540.g004
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Knowing such rapid adaptation has a genetic basis, our goal was
to exploit the resistance mechanism and understand what
organismal function, if suitably manipulated, could maintain
antibiotic synergy for longer and so ensure the smile-frown
transition does not occur so rapidly.
We therefore conducted a whole-genome sequencing study of
independent biological replicates of both monotherapies and of the
maximally synergistic treatment sampled at the end of day 5. The
analysis revealed single nucleotide polymorphisms (SNPs) in most
replicates modifying physiology, metabolism and drug resistance,
including treatments with SNPs in marRAB and acrR (see Table 1,
Figure 7, and Section 5.3 in Text S1). Indeed, the mar regulon is
known to control a range of stress-responses in E. coli [27]
including the multidrug efflux system acrAB-tolC [28].
Rapid increases in resistance to antibiotics can occur when
regions of the genome containing resistance genes are duplicated
and whole-genome sequencing was proposed as a method to
detect such duplications [29,30]. Our analysis revealed 90% of the
independent replicates in the most synergistic combination
treatment had the same 315 Kb fragment duplicated, a region
containing several efflux pumps including acr (Table 2, Section 5.4
in Text S1). The duplication was found in monotherapies too, but
only in 30–40% of those treatments (3/10 replicates for DOX-only
and 2/6 for ERY-only).
The duplication was therefore observed significantly more for
the 50-50 combination treatment than in the ERY monotherapy
(Fisher’s exact test, P,0.035) and the DOX monotherapy (Fisher’s
exact test, P,0.02). In all 14 replicates where a duplication was
detected, it was located between positions 274,201 bp and
589,900 bp. This region contains 293 genes, among which are
12 antibiotic resistance or binding genes, 32 transporter genes and
31 transposon-related genes (Appendix B in Text S1). Cross-
resistance to antibiotics not used in the protocol is likely as three
known multi-drug efflux systems and ampicillin degradation
proteins are encoded within the duplicated region (Section 5.4 in
Text S1 and Appendix B in Text S1). Such consistent, parallel
evolution towards a 315 Kb duplication in all but one replicate of
the 50-50 combination treatment strongly suggests, therefore, that
genetic amplification of a multi-drug efflux pump is the adaptation
that confers the multi-drug resistance phenotype we observe.
To test the stronger hypothesis that a drug efflux system could be
responsible for synergy loss and the smile-frown transition, we first
developed a system-specific, physico-genetics theoretical model
(detailed in Section 6.4 of Text S1) in which cells may express a gene
whose product can pump both antibiotics from the cell with no
fitness or ATP cost. We assume the drugs have different affinities for
the pump and the model encodes three phenotypes: drug-sensitive
cells that do not express the efflux system, less sensitive cells that do
Figure 5. The smile-frown transition in empirical data and modelled bacterial densities. Shown are empirical and modelled bacterial
densities (dots and lines, respectively) for 16 different drug proportions, denoted by h and ranging from 0 (denoting ERY) to 1 (denoting DOX) on the
horizontal axis. Population densities, measured as optical densities, are plotted against drug proportion are shown here in a panel of six time points
with each blue and red datum 24 hours apart. The data was obtained using E. coli K12 (MC4100) challenged by erythromycin and doxycycline. The
smile-frown transition described in the text occurs near 30 h at which point drug synergism is replaced by an antagonism. The model assumes multi-
drug efflux is the only resistance mechanism and interpolates the discrete dataset to produce a series of continuous interaction profiles, as shown.
doi:10.1371/journal.pbio.1001540.g005
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and a third phenotype then possesses an additional efflux gene and
expresses both. Figure 5 shows that the model successfully captures
the first 48 h of data predicting that the rapid inversion of synergy
that we observe empirically is consistent with the up-regulation and
duplication of efflux genes.
Generalising this mathematical framework, we can show that the
short-term optimal combination, represented by hsyn, and the time-
dependent optimal combination hopt(T) are close in general for a
time that depends on the convexity of the drug interaction profile
(Section 8.2 in Text S1). The two quantities are related as follows:
hopt(T)~hsynzr:Tz O(T
2)
zﬄﬄ}|ﬄﬄ{terms smaller than linear
ð3Þ
where T is treatment duration, r is the divergence rate between the
optimal treatment and maximal synergy; r may be positive or
negative depending on how the bacteria adapt to each drug. The
times
Tsynergy-loss&(1{hsyn)=r or Tsynergy-loss&{hsyn=r ð4Þ
are therefore approximations of the moment at which the optimal
protocol is a monotherapy and no longer a combination. Figures 2(b),
3 and 5 all exhibit this phenomenon, but it can be seen most clearly in
Figure 4(c) that shows the dynamical path taken by the best and the
worst therapies. Analogous to a critical transition, a shift takes place at
30 h of treatment where the 50-50 therapy displaces the DOX
monotherapy as the worst treatment. The synergistic treatment never
recovers its previously favourable status rather, as Figure 3(b) shows in
red, its performance continues to deteriorate exponentially.
The physico-genetics model predicts the drug interaction profile
will be robust to changes in the duration of treatment, which can
be interpreted as r being reduced in magnitude and so synergy
maintained, if the efflux system were suppressed (Figure S16 in
Text S1). This is analogous to setting m=0 in Equation 1 above.
To test this prediction we repeated the original evolutionary
protocol using two new E. coli strains: a wild-type strain AG100
and a mutant AG100A(Dacr) [31]; we refer to Section 7 of Text S1
that details the minor differences between the first and now this
evolutionary protocol. The latter strain differs from the former
through a large deletion in acrAB that renders efflux systems that
use the products of this operon, like acrAB-tolC, inoperable. As
already observed using the E. coli K12 strain MC4100, AG100
soon exhibited the smile-frown transition, within 48 h according to
Figure 8(a). In contrast, the mutant strain AG100A(Dacr) that lacks
acrAB continued to exhibit synergy until 72 h according to
Figure 8(b), consistent with the prediction.
Figure 6. Drug checkerboards and isobolograms. (a) Empirical dose-response checkerboards show population density data on the z-axis versus
drug concentration on the x and y-axes. This data was obtained by culturing E. coli sampled from the highly synergistic 50-50 environment at days
one and five (the treatment with 4.8 mg/ml ERY and 0.08 mg/ml DOX), it corroborates the known synergism on day 1 and indicates the appearance of
a more complex interaction by day 5. Note, 50% inhibition relative to the zero-drug control population is indicated by white blocks; (right) the 70%
isobole is highlighted as a green line, indicating an interaction where one drug appears to suppress the other. (b) Isoboles (lines of equal inhibitory
effect) are shown based on a numerical filter of the data from (a) (the fitting algorithm and code are described in [50]). Black lines correspond to
isoboles in intervals of 10% inhibition, the darkest red areas illustrate increasing drug concentrations with inhibition towards 100%, the darkest blue
areas denote inhibition closest to 0%. The white region denotes 50% inhibition.
doi:10.1371/journal.pbio.1001540.g006
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Dose-Dependence: Higher Doses Amplify the Smile-
Frown Transition
We now ask whether the synergy loss we observe is contingent
on the choice of D50 and E50 as basal drug concentrations. For
example, might synergy be maintained for longer if we were to
increase the dosage of both drugs? We address this question with
the following experiment.
We re-ran the drug-specific mathematical model (Section 6.4 in
Text S1) at different dosages and repeated the evolutionary
protocol using four different pairs of basal drug concentrations,
Table 1. Overview of single nucleotide polymorphisms in the genomes of E. coli K12 (MC4100) that evolved within five days in
erythromycin, doxycycline treatments or in a 50-50 combination of both.
Treatment Gene Polymorphic Sites Frequency in Replicates Annotation
Doxycycline marR 7 0.5 Repressor of marRAB operon (controls antibiotic resistance and
oxidative stress genes)
mdaB 1 0.1 NADPH quinone reductase
agaS 1 0.1 Tagatose-6-phosphate ketose/aldose isomerase
ascF 1 0.1 Phosphotransferase system IIC components (carbohydrate
transport)
eco 1 0.1 Serine protease inhibitor
Erythromycin acrR 1 0.2 acrRAB antibiotic transporter operon
ycbZ 2 0.6 ATP-dependent protease
50-50 combination rcnA 1 0.1 Membrane protein conferring nickel and cobalt resistance
evgS 1 0.1 Hybrid sensory histidine kinase in two-component regulatory
system
The number of polymorphic sites indicates how many independent nucleotide positions in the gene carry a SNP in at least one replicate, the frequency reflects the
number of replicates where a polymorphism in the gene was found. The table only shows SNPs unique to the three treatments.
doi:10.1371/journal.pbio.1001540.t001
Figure 7. Coverage plots highlight the suspected duplication: a 26increase in coverage suggests a gene duplication. A 315 Kb region
of the E. coli K12 (MC4100) genome contains the acrAB operon and is highlighted in red. The region was not duplicated for treatments with no
antibiotic (‘No drug’), it was duplicated for monotherapies (both ‘ERY’ and ‘DOX’) but was duplicated most often for combination treatments with the
greatest synergy (‘50-50’). The outer ring (black line) indicates genome position, grey blocks encompass the different replicates of each treatment
(replicates are marked with an alphabetic label) and the reddest regions are most likely to have been duplicated.
doi:10.1371/journal.pbio.1001540.g007
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chosen as follows. By analogy with (3) each new treatment can be
represented by a pair of concentrations
(D,E)~(hD40,(1{h)E40),(hD80,(1{h)E80),(hD90,(1{h)E90)
and (hD95,(1{h)E95):
Empirically, we calibrated these four concentration pairs to
produce a 40%, 80%, 90% and 95% reduction in growth relative
to a zero-drug control by 18 h on day 1 for the 50-50 treatments
(ones with h=1/2). We then subjected AG100 to treatments at
each of the four basal dosages for a duration of five days using the
drug proportions h=0,1/4,2/4,3/4, and 1.
Table 2. Several antibiotic-binding and resistance genes are found in the 315 Kb genomic region duplicated most frequently in
the 50-50 combination treatment, including the following genes and their annotations.
Start Position End Position Gene Annotation
297113 298270 ampH b-Lactam binding protein AmpH
370854 372626 mdlA Putative multidrug transporter membrane/ATP-binding components
3383237 386386 acrB Multidrug efflux protein
360871 363225 lon DNA-binding ATP-dependent protease La
386409 387602 acrA Multidrug efflux protein
387744 388391 acrR Regulates the acrAB operon
72619 374400 mdlB Putative multidrug transporter membrane/ATP-binding components
405459 406679 fsr Putative fosmidomycin efflux system
470298 470630 emrE Member of the SMR family of transporters. In E. coli this provides resistance against positively
charged compounds including ethidium bromide and erythromycin; proton-dependent
transporter exchanging protons for compound translocation (multidrug efflux protein).
564735 565946 dacA Penicillin-binding protein; removes C-terminal D-alanyl residues from sugar-peptide cell wall
567184 568296 mrdB Cell wall shape-determining protein
568299 570200 mrdA Penicillin-binding protein
doi:10.1371/journal.pbio.1001540.t002
Figure 8. The deletion of one operon in strain AG100 stabilises antibiotic synergy. (a) The strain E. coli K12 (AG100) undergoes the smile-
frown transition within two days (the value of a from the a-test is shown in the left figure and quoted 6 s.e.; day-1 a-test at 18 h: a.0, df=27,
t= 14.84, p,10213 with hopt(18 h) = 0.0460.01; day-2 a-test at 18 h: a,0, df= 27, t=27.45, p,10
27). The right-hand plot shows a dynamic of the
value of 2a from the a-test through time with antagonism following synergy where the plot passes through zero, just as in Figure 4 for the strain
MC4100. (b) E. coli K12 AG100A(Dacr) does not exhibit the smile-frown transition by day 3 and the drug interaction is still synergistic then (a-test at
24 h on day 3: a.0, df= 27, t<3.95, p,0.00052; see Section 7.2 in Text S1). The right-hand figure shows that the plot of 2a from the a-test does not
pass through zero at any time, the drug interaction is therefore stable and synergistic over the entire period of observation.
doi:10.1371/journal.pbio.1001540.g008
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The prior mathematical model made a quantitative prediction
for this new protocol that is depicted in Figure 9(a): the greater the
antibiotic dose, the greater the synergy observed on day 1 and the
greater the resulting antagonism on day 2 (see also Figure 9(b)).
These figures show the model predicts that synergy is maintained
from the first day onwards only when the dosages are sufficiently
low.
Figure 9(c) shows the results of this experiment are in
quantitative agreement with the model. Indeed, the numerical
values of day-one synergy and day-two antagonism are
positively correlated in both the model and the resulting data
(R2 = 0.990, F= 145, p,0.0069) provided the antibiotic dose is
sufficiently high in the former. Finally, we observe more rapid
selection for resistance at higher doses in the sense that the
greater the dose, the sooner the transition to antagonism
(Section 7.3 in Text S1).
Discussion
It is important to state that we, of course, exercise extreme
caution when drawing parallels with in vivo infections where the
immune response, the highly-organised spatial structure of the
host, xenobiotic metabolism and the pharmacokinetics that result
may substantially complicate antibiotic interaction dynamics.
However, we also argue that in vitro evolutionary studies of
bacteria allied to genome-wide analyses and mathematical
modelling can play an important role in elucidating how antibiotic
interactions change through time precisely because model systems
like ours are so simple.
Drug interactions are subtle and synergy can be lost, and
inverted, for reasons other than competitive release. Synergy
must decay with time because of selection for drug-resistant
alleles but it can be inverted when drugs degrade to produce
Figure 9. The stronger the synergy on day 1, the stronger the antagonism on day 2, both in models and data. (a) A theoretical model
trained on prior predicts that the difference between 18 h synergy and 42 h antagonism will be greater at greater doses. (The prior training data is
included in one of the panes and basal dosages are given within each pane.) (b) Predicted changes in interaction are shown as blue points that were
determined using a values from the simulations in (a) above. Alongside these are the analogous a values from data in (c) which are black, the dashed
line is the linear regression from (c). (c) The correlation between day 1 synergy and day 2 antagonism measured empirically at different basal dosages
can be seen in this linear regression showing the interaction measure a at 12 h versus a at 48 h (see Materials and Methods for the definition of a;
horizontal and vertical lines are s.e.). Labels denote the level of growth inhibition, 40, 80, 90 and 95%, observed at 18 h relative to a zero-drug control
for each of four basal drug dosages.
doi:10.1371/journal.pbio.1001540.g009
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non-antibiotic metabolites [26]. It is known that drug interac-
tions can depend upon population heterogeneities because of
differential pump expression between subpopulations [32], but
cellular mechanisms not commonly associated with resistance
might also force drug interactions to change with time. For
example, a theoretical model was used to propose [33] that
synergism and antagonism could be found simultaneously in a
population of cancer cells due to metabolic adaptation in
subpopulations, the so-called Harvey Effect [34]. To our
knowledge, this theory has not been tested.
There are parallels with a prior study [14] that used antagonistic
and synergistic antibiotic pairs to show that synergistic environ-
ments promote resistance more quickly than do antagonistic ones
and the analogy of their result in our data is Figure 10. Their core
argument, that single drug-resistance mutations have a greater
fitness effect in more synergistic environments is applicable to our
study and consistent with our findings. Unlike ours, however, that
study did not address which treatments lead to the lowest or
greatest bacterial loads.
Nothing of the molecular, multi-drug resistance mechanism
is encoded within Equation 1 and despite its simplicity, this
model may explain other phenomena. This includes the
unreliability of antibiotic synergy assays such as checkerboards
[35–37]. If a drug interaction assay were conducted with
resistant cells in the inoculum [32] or if one emerged,
irrespective of genetic mechanism, Equation 1 predicts synergy
and antagonism could be reported for two replicates of the
same checkerboard [37]. Indeed Figure 4(c) illustrates how the
change from synergistic to antagonistic interaction can occur
quickly and it is only when population density data is
sufficiently well-resolved through time that a transition point
from one to the other is found.
Our theoretical models are consistent with the smile-frown
transition not being specific either to the drugs used or to the
bacterium, any multi-drug resistance mechanism inactive in the
absence of drugs that confers a fitness advantage in their
presence may be sufficient (Section 8 in Text S1). However,
while our data establishes that the duplication of a chromosomal
multi-drug efflux operon is sufficient to observe the transition,
this has been done for one Gram negative bacterial species and
one drug pair.
Many questions therefore remain regarding the generality of
our observations. Clinically-important pathogens are known to
efflux drugs into extracellular space, or the periplasm, thus
conferring resistance to a wide range of drugs in many species
[38,39]. As efflux has been observed both in clinical Staphylococcus
aureus [40] and Mycobacterium tuberculosis (TB) [41] we ask whether
synergy loss or the smile-frown transition might be observed in
other bacteria. Relevant to this question is the study [35] of several
clinical isolates of methicillin-susceptible and -resistant S. aureus
(MSSA and MRSA) in which a combination of vancomycin and
rifampin was variously reported as synergistic and antagonistic at
24 h and 48 h, with different interactions reported for both
different strains and different drug concentrations. No mechanistic
explanation has been attributed to this discrepancy and while this
may not be at all related to efflux, the true nature of this important
combination remains unclear [42].
What of drug combinations reliant on different mechanisms of
synergy [43]? The duplicated genomic region illustrated in Figure 7
contains dacA with b-lactamase activity [44] and three efflux systems
in addition to acr. Efflux of fosmidomycin by far [45], of aminoglycosides
by emrE and of fluoroquinolones by mdlAB [39], all of which are found
in the duplicated region (Table 2), indicates the smile-frown
transition may also be relevant to other classes of antibiotics.
And would the transition still be observed if two target-altering,
de novo mutations were needed for multi-drug resistance because
there were no pre-existing chromosomal resistance mechanism
that could be so rapidly duplicated? We have not been able to
determine a pair of such mutations and so, by way of a partial
response, we compared the duration for which synergy is
maintained when an important chromosomally-encoded multi-
drug pump is, and is not, present using data from E. coli strains
AG100 and AG100A(Dacr). Figure 8(a) shows that synergy is lost to
antagonism in the former strain around 35 h but for the latter
strain, the interaction only ceases to be significantly synergistic
around 72 h, although significant antagonism is not observed
thereafter. The latter strain, without acr, does therefore exhibit
synergy loss but the smile-frown transition was not observed.
However, in this case the interaction converges towards indiffer-
ence in which one of the combination treatments maximises
population densities by day 4 but without the smile-frown
transition ever appearing (Section 7.2 in Text S1).
It has been suggested that the treatment of multi-drug resistant
TB will be more successful if supplemented with efflux pump
inhibitors (EPIs) [39,46]. The present work suggests that if EPIs
are used as an adjuvant to combination therapy they may prove
beneficial by maintaining synergy for longer, although we have not
conducted a direct test of this hypothesis using an EPI molecule.
We conclude that complementary theoretical and in vitro
approaches agree that the optimal way of combining antibiotics
depends on the duration of treatment. This could have been
deduced from a simple engineering principle that complex
adaptive systems cannot be controlled optimally using strategies
that are constant through time (Section 8.2 in Text S1). The
consequences of this principle for antibiotic combinations are
dramatic and cause the emergence of what looks like antagonism
from a synergism, rendering the supposed optimal combination
the worst treatment of all within a day. So while it is axiomatic in
theory [18] and demonstrable empirically [14] that drug resistance
rises faster for more synergistic treatments, that the greatest
antibiotic potency can also select for the highest bacterial densities
has been overlooked.
Figure 10. The greater the synergy, the more rapid adaptation
is to treatment. This illustrates an entirely expected aspect of our data
that corroborates a previous finding [14] on differences in rates of
adaptation between antibiotic treatments using different drug pairs:
selection for resistance is greater when treatments are more synergistic.
The figure shows that our data also supports this idea (degree of
interaction defined in Materials and Methods; rate of adaptation is
defined in Section 4 of Text S1).
doi:10.1371/journal.pbio.1001540.g010
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Materials and Methods
Experimental Protocol
The protocol is a standard batch-transfer protocol used
elsewhere [14] in the context of antibiotic treatments and
described in detail in Section 3 of Text S1. Briefly: bacteria are
cultured in liquid growth medium for 24 h in the presence and
absence of different antibiotics and continually shaken. Optical
density measurements are taken continually from where the
inhibition due to treatment can be calculated relative to the
growth observed in a control cultured without drugs. After each
24 h period has elapsed, the environment is sampled and
approximately 1% of biomass transferred to fresh a environment
that includes replenished growth medium and drugs. This process
was repeated for 5 days.
Quantifying Drug Synergy
There are many nonequivalent definitions of antibiotic synergy
[8,17,47–49]. To ensure a precise quantification of drug interac-
tions we use several consistent measures with different granularity
derived with Loewe additivity as the key assumption. Suppose
bacterial growth is measured over a fixed and short length of time,
usually 24 h in the literature, although our measurements will be
substantially longer. Population density is denoted by the function
B(D,E) where D and E are extra-cellular drug concentrations, the
number B(0,0) then represents density in a zero-drug environment.
Assume each basal concentration, D and E, have been normalised
to equal inhibitory effect, thus B(D,0) =B(0,E) = rB(0,0). The value
r~ 1
2
corresponds to the choice of IC50 for D and E, the
concentrations denoted D50 and E50 in the text.
Quantification of the drug interaction begins with i, the
interaction profile, where i(h) =B(hD,(12h)E). Following Loewe
additivity [8], i is said to be synergistic if, for all h between zero
and one exclusive, the effect of the drugs combined is greater than
the sum of effects produced by each drug separately:
i hð Þvh:i 1ð Þz 1{hð Þ:i 0ð Þ
~rB(0,0):
independent of h by constructionð Þ
ð5Þ
This definition is described pictorially in Figure 1, Figures 1(b) and
1(d) are particularly relevant. Property (5) holds necessarily if i(h) is
convex (c.f. blue lines in Figures 2(b) and 5). When property (5)
does hold it follows that hsyn, the maximally synergistic drug
proportion that satisfies
i(hsyn)~ min
0ƒhƒ1
i(h)
also satisfies 0,hsyn,1. Drug antagonism is said to occur when the
reverse inequality applies in (5), this is necessarily the case if i(h) is
concave. The drug interaction is additive in this context if i(h) is
independent of h.
Bacterial density is measured empirically over a time period of
length T hours, so we now introduce T into the definition of B.
Denote density by B(T;D,E ) and re-write i as i(h,T ) to account for
the change. The time-dependent optimal combination, hopt(T ),
then satisfies
i(hopt(T),T)~ min
0ƒhƒ1
i(h,T): ð6Þ
It follows by definition that hopt(T ) and hsyn are equal when T=0
and are therefore also close for small T , Equation 3 describes the
rate of divergence between the two.
If we define the dimensionless interaction profile
id (h,T)~{rz
B(T ; hD,(1{h)E)
B(T ; 0,0)
,
the degree of interaction, I(T ), is given by the mean interaction
taken over the relevant drug combinations:
I(T)~
ð1
0
id (h,T)dh:
Negative I(T ) denotes synergy, positive I(T ) denotes antagonism.
A measure of the convexity and concavity of i(h,T ) obtained by
fitting a quadratic, q(h)~ah2zbhzc, can be used to assess the
drug interaction. Significant positivity (obtained using a t-test) of a
indicates synergy, negativity indicates antagonism; Section 7 in Text
S1 gives further information on the use of this test. If the density
data is significantly nonlinear as a function of h, meaning a?0, the
fitted quadratic can be used to robustly estimate the drug
proportion that maximises bacterial density at each time. This
proportion is given by one of h=0,1 or 2b/(2a) depending on
which value is the lowest of q(0), q(1) or q(2b/(2a)). Provided 2b/
(2a) lies between 0 and 1, an approximate upper bound on the
confidence interval for this optimal value can be found from a t-
test that returns confidence intervals for a, b, and c. Throughout
we will refer to the test described in this paragraph as the ‘a-test’
and it is implemented using the regression facilities in the Statistics
Toolbox of MATLAB.
Supporting Information
Text S1 Supporting information. This file includes nine
sections and two appendices: 1. Introduction: hit early, hit hard? 2.
Drug interaction profiles: synergy and antagonism. 3. Experimen-
tal evolution in a two-drug environment: methods. 4. Experimen-
tal evolution in a two-drug environment. 5. Analysis: whole
genome sequencing. 6. Analysis: a mathematical model consistent
with data. 7. Validating the theory: testing the smile-frown
experiment with an acrAB knockout. 8. Optimal drug combina-
tions are not constant: an analysis. 9. Final comment: single cell
synergy and population synergy. Appendix A: Parameter values.
Appendix B: Genes annotated in the duplicated regions.
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